...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Korean Circulation Journal >The Effect of Primary Percutaneous Coronary Intervention after the Administration of Tirofiban Alone or Tirofiban Combined with Low dose Alteplase in Patients with Acute Myocardial Infarction on ST Elevation Resolution, TIMI Flow and Short-Term Clinical Ou
【24h】

The Effect of Primary Percutaneous Coronary Intervention after the Administration of Tirofiban Alone or Tirofiban Combined with Low dose Alteplase in Patients with Acute Myocardial Infarction on ST Elevation Resolution, TIMI Flow and Short-Term Clinical Ou

机译：急性心肌梗死患者单独给予替罗非班或替罗非班联合低剂量阿替普酶联合初次经皮冠状动脉介入治疗对ST升高分辨率，TIMI流量和短期临床剂量的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND OBJECTIVES: The combination of platelet glycoprotein IIb/IIIa inhibitors and a low dose thrombolytic agent may produce early Thrombolysis In Myocardial Infarction (TIMI) 3 flow and a high rate of ST elevation resolution in an ST elevation acute myocardial infarction (STEMI). The clinical effect of tirofiban combined with low dose alteplase, prior to primary percutaneous coronary intervention (PCI) in STEMI, were evaluated on the ST elevation resolution, TIMI flow and 30-day clinical outcomes. SUBJECTS AND METHODS: Following aspirin, clopidogrel and standard heparin, 45 patients with STEMI were randomized into 2 groups; tirofiban administration (Group I; n=23, 64±10 years; 15 male) or combined administration of tirofiban with 40 mg alteplase prior to primary PCI (Group II; n=22, 59±11 years; 19 male). The pre- and post-interventional TIMI flow grades, ST elevation resolution and bleeding complications were compared between the two groups. The major adverse cardiac events (MACE) were compared between the two groups during 30-days of clinical follow-up. RESULTS: Group II had a higher pre-interventional TIMI flow (TIMI flow≥2: 34.8% vs. 90.9%, p CONCLUSION: Combined administration of tirofiban with alteplase prior to primary PCI leads to a higher TIMI flow and more frequent ST elevation resolution, without bleeding complications, compared to a single administration of tirofiban.
机译：背景和目的：血小板糖蛋白IIb / IIIa抑制剂与低剂量溶栓剂的组合可能会在ST抬高急性心肌梗死（STEMI）中产生早期的心肌梗塞（TIMI）3血流溶解和高ST抬高分辨率。在STEMI初次经皮冠状动脉介入治疗（PCI）之前，对替罗非班联合低剂量阿替普酶的临床效果进行了ST抬高分辨率，TIMI流量和30天临床结局的评估。研究对象和方法：将45例STEMI患者接受阿司匹林，氯吡格雷和标准肝素治疗后随机分为2组。替罗非班给药（I组; n = 23，64±10岁;男性15）或在初次PCI之前联合使用替罗非班与40 mg阿替普酶（II组; n = 22，59±11岁;男性19）。比较了两组干预前后的TIMI血流分级，ST抬高分辨力和出血并发症。在临床随访的30天中比较了两组的主要不良心脏事件（MACE）。结果：第二组介入前TIMI血流较高（TIMI血流≥2：34.8％比90.9％，p）结论：在主要PCI之前联合使用替罗非班和阿替普酶可导致更高的TIMI血流和更频繁的ST抬高分辨率与单次服用替罗非班相比，没有出血并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号